Log in to your Inderes Free account to see all free content on this page.

Cantargia

4.43 SEK

+6.12 %

1,289 following

CANTA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+6.12 %

+23.95 %

+75.94 %

+254.00 %

+161.83 %

+140.62 %

+29.01 %

-92.06 %

-37.39 %

Cantargia operates in the pharmaceutical industry and focuses on the development of treatments for cancer and inflammatory diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Cantargia was founded in 2009 and is headquartered in Lund, Sweden.

Market cap

1.1B SEK

Turnover

30.29M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

20.2.

2026

Annual report '25

19.5.

2026

Interim report Q1'26

21.5.

2026

General meeting '26

All

Webcasts

Press releases

3rd party

ShowingAll content types

Press release11/20/2025, 2:15 PM

Redeye: Cantargia (Q3 Review) - Planning for a Pivotal Study of Nadunolimab

Cantargia, Audiocast, Q3'25

Webcast11/19/2025, 2:00 PM

Cantargia, Audiocast, Q3'25

Press release11/19/2025, 7:37 AM

BioStock: Video from Cantargias's presentation at BioStock Life Science Summit 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/19/2025, 6:00 AM

Cantargia Publishes Interim Report for January to September 2025

Regulatory press release11/12/2025, 7:45 AM

Cantargia presents Nomination Committee ahead of 2026 AGM

Press release11/5/2025, 8:30 AM

Invitation to the Presentation of Cantargia’s Interim Report January-September 2025

Press release10/23/2025, 11:30 AM

Cantargia to Participate in Upcoming Conferences

Press release10/7/2025, 11:27 AM

BioStock: Cantargia:”Our data is very compelling”

Regulatory press release10/2/2025, 5:30 AM

Cantargia appoints Dr. Wolfram Dempke as Chief Medical Officer

Press release9/30/2025, 10:00 PM

Cantargia presents data at an AACR Conference strengthening IL1RAP as a targetable hallmark in PDAC

Press release9/25/2025, 9:32 AM

BioStock: Video from Cantargias presentation at BioStock Investing in Life Science – From Seed to Success

Regulatory press release9/11/2025, 5:30 AM

Cantargia closes the acquisition of CAN10 by Otsuka

Press release8/27/2025, 5:30 AM

Cantargia granted important US patent for nadunolimab

Press release8/25/2025, 9:25 AM

Redeye: Cantargia Q2 2025 - Major Deal and Negative TRIFOUR Readout

Cantargia, Audiocast, Q2'25

Webcast8/21/2025, 1:00 PM

Cantargia, Audiocast, Q2'25

Regulatory press release8/21/2025, 5:00 AM

Cantargia publishes half-year report 2025

Regulatory press release8/18/2025, 4:25 PM

Cantargia appoints Dr Hilde Steineger as Chief Executive Officer

Press release8/12/2025, 8:15 AM

Invitation to the presentation of Cantargia’s H1 2025 report

Regulatory press release7/17/2025, 7:30 PM

Cantargia announces preliminary topline efficacy results from the phase 2 TRIFOUR trial of nadunolimab in advanced triple-negative breast cancer (TNBC)

Press release7/17/2025, 10:25 AM

BioStock: Otsuka Pharmaceutical acquires Cantargia’s CAN10 program in a deal worth over USD 600 million

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.